• Open Access
    Review

    Helicobacter pylori and gastric cancer: a critical approach to who really needs eradication

    Elias Kouroumalis 1,2*
    Ioannis Tsomidis 2
    Argyro Voumvouraki 3

    Explor Dig Dis. 2024;3:107–142 DOI: https://doi.org/10.37349/edd.2024.00043

    Received: October 21, 2023 Accepted: February 20, 2024 Published: April 16, 2024

    Academic Editor: Tzi-Bun Ng, The Chinese University of Hong Kong, China

    This article belongs to the special issue Helicobacter Pylori and Infection: Genomics, Diagnosis, Pathogenesis, Antibiotic Resistance, Microbiota, Cancer, Prevention and Therapeutics

    Abstract

    It is generally accepted that eradication of Helicobacter pylori (H. pylori) infection may reduce the risk of the development of gastric cancer. Recommendations for global generalized tests and treat all individuals detected positive for H. pylori infection are currently proposed. However, the bacterium is commensal and harmless for the vast majority of the infected population. Moreover, eradication may have detrimental consequences in several groups of patients. In the present review, the current epidemiological data and recommendations for eradication in connection with the possible beneficial effects of the colonization with H. pylori in diseases such as asthma and allergies or chronic gastro-intestinal disorders such as inflammatory bowel disease and Barrett’ esophagus are presented the problems with increasing antibiotic resistance were also examined. Specific groups of patients where eradication of H. pylori may be necessary and endoscopic surveillance is advised were identified. Finally, based on the paradox of high H. pylori prevalence and low gastric risk as reported for areas of Africa, Asia, South America, and Greece, alternatives that may replace the widespread eradication of H. pylori with equal if not better results and more prudent use of the available financial resources are proposed. Mediterranean diets and alcohol and smoking reduction are among the well documented alternatives.

    Keywords

    Helicobacter pylori, eradication, gastric cancer, Mediterranean diet

    Abbreviations

    AG:

    atrophic gastritis

    ARF:

    ADP-ribosylation factor

    ATGs:

    autophagy related genes

    BMI:

    body mass index

    CagA:

    cytotoxin-associated gene A

    CD:

    Crohn’s disease

    DC:

    dendritic cell

    ESCC:

    esophageal squamous cell carcinoma

    FUT2:

    fucosyl transferase 2

    GC:

    gastric cancer

    H. pylori:

    Helicobacter pylori

    IBD:

    inflammatory bowel disease

    ICER:

    incremental cost effectiveness

    IL-8:

    interleukin-8

    IM:

    intestinal metaplasia

    MALT:

    mucosa-associated lymphoid tissue

    MD:

    Mediterranean diet

    OLGA:

    operative link for gastritis assessment

    OLGIM:

    operative link for gastric intestinal metaplasia assessment

    OMVs:

    outer membrane vesicles

    OR:

    odds ratio

    PAMPs:

    pathogen associated molecular patterns

    PPIs:

    proton pump inhibitors

    QALY:

    quality-adjusted life year

    QoL:

    quality of life

    SPEM:

    spasmolytic polypeptide-expressing metaplasia

    UC:

    ulcerative colitis

    VacA:

    vacuolating cytotoxin A

    Declarations

    Author contributions

    EK: Conceptualization, Investigation, Writing—original draft, Writing—review & editing, Supervision. IT: Writing—original draft, Writing—review & editing. AV: Writing—review & editing. All authors read and approved the submitted version.

    Conflicts of interest

    The authors declare that they have no conflicts of interest.

    Ethical approval

    Not applicable.

    Consent to participate

    Not applicable.

    Consent to publication

    Not applicable.

    Availability of data and materials

    Not applicable.

    Funding

    Not applicable.

    Copyright

    © The Author(s) 2024.

    References

    Kotilea K, Bontems P, Touati E. Epidemiology, diagnosis and risk factors of Helicobacter pylori infection. In: Kamiya S, Backert S, editors. Helicobacter pylori in human diseases: advances in microbiology, infectious diseases and public health. Cham: Springer; 2019. pp. 17–33. [DOI] [PubMed]
    Hooi JKY, Lai WY, Ng WK, Suen MMY, Underwood FE, Tanyingoh D, et al. Global prevalence of Helicobacter pylori infection: systematic review and meta-analysis. Gastroenterology. 2017;153:4209. [DOI] [PubMed]
    Bordin D, Morozov S, Plavnik R, Bakulina N, Voynovan I, Skibo I, et al. Helicobacter pylori infection prevalence in ambulatory settings in 2017–2019 in RUSSIA: the data of real-world national multicenter trial. Helicobacter. 2022;27:e12924. [DOI] [PubMed]
    Mezmale L, Coelho LG, Bordin D, Leja M. Review: epidemiology of Helicobacter pylori. Helicobacter. 2020;25:e12734. [DOI] [PubMed]
    den Hollander WJ, Holster IL, den Hoed CM, van Deurzen F, van Vuuren AJ, Jaddoe VW, et al. Ethnicity is a strong predictor for Helicobacter pylori infection in young women in a multi-ethnic European city. J Gastroenterol Hepatol. 2013;28:170511. [DOI] [PubMed] [PMC]
    Liou JM, Malfertheiner P, Lee YC, Sheu BS, Sugano K, Cheng HC, et al. Screening and eradication of Helicobacter pylori for gastric cancer prevention: the Taipei global consensus. Gut. 2020;69:2093112. [DOI] [PubMed]
    Zamani M, Ebrahimtabar F, Zamani V, Miller WH, Alizadeh-Navaei R, Shokri-Shirvani J, et al. Systematic review with meta-analysis: the worldwide prevalence of Helicobacter pylori infection. Aliment Pharmacol Ther. 2018;47:86876. [DOI] [PubMed]
    Malaty HM, El-Kasabany A, Graham DY, Miller CC, Reddy SG, Srinivasan SR, et al. Age at acquisition of Helicobacter pylori infection: a follow-up study from infancy to adulthood. Lancet. 2002;359:9315. [DOI] [PubMed]
    Kivi M, Tindberg Y, Sörberg M, Casswall TH, Befrits R, Hellström PM, et al. Concordance of Helicobacter pylori strains within families. J Clin Microbiol. 2003;41:56048. [DOI] [PubMed] [PMC]
    Malfertheiner P, Camargo MC, El-Omar E, Liou JM, Peek R, Schulz C, et al. Helicobacter pylori infection. Nat Rev Dis Primers. 2023;9:19. [DOI] [PubMed]
    Schulz C, Schütte K, Mayerle J, Malfertheiner P. The role of the gastric bacterial microbiome in gastric cancer: Helicobacter pylori and beyond. Therap Adv Gastroenterol. 2019;12:1756284819894062. [DOI] [PubMed] [PMC]
    de Martel C, Georges D, Bray F, Ferlay J, Clifford GM. Global burden of cancer attributable to infections in 2018: a worldwide incidence analysis. Lancet Glob Health. 2020;8:e18090. [DOI] [PubMed]
    Shirani M, Pakzad R, Haddadi MH, Akrami S, Asadi A, Kazemian H, et al. The global prevalence of gastric cancer in Helicobacter pylori-infected individuals: a systematic review and meta-analysis. BMC Infect Dis. 2023;23:543. [DOI] [PubMed] [PMC]
    Rawla P, Barsouk A. Epidemiology of gastric cancer: global trends, risk factors and prevention. Prz Gastroenterol. 2019;14:2638. [DOI] [PubMed] [PMC]
    Fann JC, Chiang TH, Yen AM, Lee YC, Wu MS, Chen HH. Personalized risk assessment for dynamic transition of gastric neoplasms. J Biomed Sci. 2018;25:84. [DOI] [PubMed] [PMC]
    Arnold M, Moore SP, Hassler S, Ellison-Loschmann L, Forman D, Bray F. The burden of stomach cancer in indigenous populations: a systematic review and global assessment. Gut. 2014;63:6471. [DOI] [PubMed]
    Kumar S, Metz DC, Ellenberg S, Kaplan DE, Goldberg DS. Risk factors and incidence of gastric cancer after detection of Helicobacter pylori infection: a large cohort study. Gastroenterology. 2020;158:52736.e7. [DOI] [PubMed] [PMC]
    González CA, López-Carrillo L. Helicobacter pylori, nutrition and smoking interactions: their impact in gastric carcinogenesis. Scand J Gastroenterol. 2010;45:614. [DOI] [PubMed]
    Venneman K, Huybrechts I, Gunter MJ, Vandendaele L, Herrero R, Van Herck K. The epidemiology of Helicobacter pylori infection in Europe and the impact of lifestyle on its natural evolution toward stomach cancer after infection: a systematic review. Helicobacter. 2018;23:e12483. [DOI] [PubMed]
    Piscione M, Mazzone M, Di Marcantonio MC, Muraro R, Mincione G. Eradication of Helicobacter pylori and gastric cancer: a controversial relationship. Front Microbiol. 2021;12:630852. [DOI] [PubMed] [PMC]
    GBD 2017 Stomach Cancer Collaborators. The global, regional, and national burden of stomach cancer in 195 countries, 1990–2017: a systematic analysis for the Global Burden of Disease study 2017. Lancet Gastroenterol Hepatol. 2020;5:4254. [DOI] [PubMed] [PMC]
    Roberts SE, Morrison-Rees S, Samuel DG, Thorne K, Akbari A, Williams JG. Review article: the prevalence of Helicobacter pylori and the incidence of gastric cancer across Europe. Aliment Pharmacol Ther. 2016;43:33445. [DOI] [PubMed]
    Lin Y, Zheng Y, Wang HL, Wu J. Global patterns and trends in gastric cancer incidence rates (1988–2012) and predictions to 2030. Gastroenterology. 2021;161:11627.e8. [DOI] [PubMed]
    Valle J, Kekki M, Sipponen P, Ihamäki T, Siurala M. Long-term course and consequences of Helicobacter pylori gastritis results of a 32-year follow-up study. Scand J Gastroenterol. 1996;31:54650. [DOI] [PubMed]
    Sipponen P, Kekki M, Siurala M. Atrophic chronic gastritis and intestinal metaplasia in gastric carcinoma. Comparison with a representative population sample. Cancer. 1983;52:10628. [DOI] [PubMed]
    Alipour M. Molecular mechanism of Helicobacter pylori-induced gastric cancer. J Gastrointest Cancer. 2021;52:2330. [DOI] [PubMed] [PMC]
    Bornschein J, Pritchard DM. Myths and misconceptions in the management of Helicobacter pylori infection. Frontline Gastroenterol. 2021;13:24553. [DOI] [PubMed] [PMC]
    Chen HN, Wang Z, Li X, Zhou ZG. Helicobacter pylori eradication cannot reduce the risk of gastric cancer in patients with intestinal metaplasia and dysplasia: evidence from a meta-analysis. Gastric Cancer. 2016;19:16675. [DOI] [PubMed]
    Abadi ATB. Strategies used by helicobacter pylori to establish persistent infection. World J Gastroenterol. 2017;23:287082. [DOI] [PubMed] [PMC]
    Lekmeechai S, Su YC, Brant M, Alvarado-Kristensson M, Vallström A, Obi I, et al. Helicobacter pylori outer membrane vesicles protect the pathogen from reactive oxygen species of the respiratory burst. Front Microbiol. 2018;9:1837. [DOI] [PubMed] [PMC]
    McClain MS, Beckett AC, Cover TL. Helicobacter pylori vacuolating toxin and gastric cancer. Toxins (Basel). 2017;9:316. [DOI] [PubMed] [PMC]
    Polk DB, Peek RM Jr. Helicobacter pylori: gastric cancer and beyond. Nat Rev Cancer. 2010;10:40314. [DOI] [PubMed] [PMC]
    Foegeding NJ, Caston RR, McClain MS, Ohi MD, Cover TL. An overview of helicobacter pylori vaca toxin biology. Toxins (Basel). 2016;8:173. [DOI] [PubMed] [PMC]
    Hatakeyama M. Helicobacter pylori CagA and gastric cancer: a paradigm for hit-and-run carcinogenesis. Cell Host Microbe. 2014;15:30616. [DOI] [PubMed]
    Freire de Melo F, Marques HS, Rocha Pinheiro SL, Lemos FFB, Silva Luz M, Nayara Teixeira K, et al. Influence of Helicobacter pylori oncoprotein CagA in gastric cancer: a critical-reflective analysis. World J Clin Oncol. 2022;13:86679. [DOI] [PubMed] [PMC]
    Palrasu M, Zaika E, El-Rifai W, Que J, Zaika AI. Role of bacterial and viral pathogens in gastric carcinogenesis. Cancers (Basel). 2021;13:1878. [DOI] [PubMed] [PMC]
    Kuo ML, Duncavage EJ, Mathew R, den Besten W, Pei D, Naeve D, et al. Arf induces p53-dependent and -independent antiproliferative genes. Cancer Res. 2003;63:104653. [PubMed]
    Wei J, Noto JM, Zaika E, Romero-Gallo J, Piazuelo MB, Schneider B, et al. Bacterial CagA protein induces degradation of p53 protein in a p14ARF-dependent manner. Gut. 2015;64:10408. [DOI] [PubMed] [PMC]
    Cai JB, Shi GM, Dong ZR, Ke AW, Ma HH, Gao Q, et al. Ubiquitin-specific protease 7 accelerates p14ARF degradation by deubiquitinating thyroid hormone receptor-interacting protein 12 and promotes hepatocellular carcinoma progression. Hepatology. 2015;61:160314. [DOI] [PubMed]
    Palrasu M, Zaika E, Paulrasu K, Caspa Gokulan R, Suarez G, Que J, et al. Helicobacter pylori pathogen inhibits cellular responses to oncogenic stress and apoptosis. PLoS Pathog. 2022;18:e1010628. [DOI] [PubMed] [PMC]
    Buti L, Spooner E, Van der Veen AG, Rappuoli R, Covacci A, Ploegh HL. Helicobacter pylori cytotoxin-associated gene A (CagA) subverts the apoptosis-stimulating protein of p53 (ASPP2) tumor suppressor pathway of the host. Proc Natl Acad Sci U S A. 2011;108:923843. [DOI] [PubMed] [PMC]
    de Brito BB, da Silva FAF, Soares AS, Pereira VA, Santos MLC, Sampaio MM, et al. Pathogenesis and clinical management of Helicobacter pylori gastric infection. World J Gastroenterol. 2019;25:557889. [DOI] [PubMed] [PMC]
    Guerrero-Mandujano A, Hernández-Cortez C, Ibarra JA, Castro-Escarpulli G. The outer membrane vesicles: secretion system type zero. Traffic. 2017;18:42532. [DOI] [PubMed]
    Tiku V, Tan MW. Host immunity and cellular responses to bacterial outer membrane vesicles. Trends Immunol. 2021;42:102436. [DOI] [PubMed]
    Choi HI, Choi JP, Seo J, Kim BJ, Rho M, Han JK, et al. Helicobacter pylori-derived extracellular vesicles increased in the gastric juices of gastric adenocarcinoma patients and induced inflammation mainly via specific targeting of gastric epithelial cells. Exp Mol Med. 2017;49:e330. [DOI] [PubMed] [PMC]
    Chmiela M, Walczak N, Rudnicka K. Helicobacter pylori outer membrane vesicles involvement in the infection development and Helicobacter pylori-related diseases. J Biomed Sci. 2018;25:78. [DOI] [PubMed] [PMC]
    Calvino Fernández M, Parra Cid T. H. pylori and mitochondrial changes in epithelial cells. The role of oxidative stress. Rev Esp Enferm Dig. 2010;102:4150. [DOI] [PubMed]
    Eletto D, Mentucci F, Voli A, Petrella A, Porta A, Tosco A. Helicobacter pylori pathogen-associated molecular patterns: friends or foes? Int J Mol Sci. 2022;23:3531. [DOI] [PubMed] [PMC]
    Castaño-Rodríguez N, Kaakoush NO, Goh KL, Fock KM, Mitchell HM. Autophagy in Helicobacter pylori infection and related gastric cancer. Helicobacter. 2015;20:35369. [DOI] [PubMed] [PMC]
    Mommersteeg MC, Simovic I, Yu B, van Nieuwenburg SAV, Bruno IMJ, Doukas M, et al. Autophagy mediates ER stress and inflammation in Helicobacter pylori-related gastric cancer. Gut Microbes. 2022;14:2015238. [DOI] [PubMed] [PMC]
    Yamaguchi N, Sakaguchi T, Isomoto H, Inamine T, Ueda H, Fukuda D, et al. ATG16L1 and ATG12 gene polymorphisms are involved in the progression of atrophic gastritis. J Clin Med. 2023;12:5384. [DOI] [PubMed] [PMC]
    Yamaguchi N, Sakaguchi T, Isomoto H, Inamine T, Tsukamoto R, Fukuda D, et al. Polymorphism in autophagy-related genes LRP1 and CAPZA1 may promote gastric mucosal atrophy. Genes Environ. 2023;45:18. [DOI] [PubMed] [PMC]
    Terebiznik MR, Raju D, Vázquez CL, Torbricki K, Kulkarni R, Blanke SR, et al. Effect of Helicobacter pylori’s vacuolating cytotoxin on the autophagy pathway in gastric epithelial cells. Autophagy. 2009;5:3709. [DOI] [PubMed]
    Raju D, Hussey S, Ang M, Terebiznik MR, Sibony M, Galindo-Mata E, et al. Vacuolating cytotoxin and variants in Atg16L1 that disrupt autophagy promote Helicobacter pylori infection in humans. Gastroenterology. 2012;142:116071. [DOI] [PubMed] [PMC]
    Yang Y, Shu X, Xie C. An overview of autophagy in Helicobacter pylori infection and related gastric cancer. Front Cell Infect Microbiol. 2022;12:847716. [DOI] [PubMed] [PMC]
    Fallone CA, Moss SF, Malfertheiner P. Reconciliation of recent Helicobacter pylori treatment guidelines in a time of increasing resistance to antibiotics. Gastroenterology. 2019;157:4453. [DOI] [PubMed]
    Howden CW. Emerging regimens for H. pylori infection should enhance efficacy and circumvent resistance. Dig Dis Sci. 2019;64:26912. [DOI] [PubMed]
    Ford AC, Forman D, Hunt R, Yuan Y, Moayyedi P. Helicobacter pylori eradication for the prevention of gastric neoplasia. Cochrane Database Syst Rev. 2020;7:CD005583. [DOI] [PubMed] [PMC]
    Ford AC, Yuan Y, Moayyedi P. Helicobacter pylori eradication therapy to prevent gastric cancer: systematic review and meta-analysis. Gut. 2020;69:211321. [DOI] [PubMed]
    Sugimoto M, Murata M, Yamaoka Y. Chemoprevention of gastric cancer development after Helicobacter pylori eradication therapy in an East Asian population: meta-analysis. World J Gastroenterol. 2020;26:182040. [DOI] [PubMed] [PMC]
    Lee YC, Chiang TH, Chou CK, Tu YK, Liao WC, Wu MS, et al. Association between Helicobacter pylori eradication and gastric cancer incidence: a systematic review and meta-analysis. Gastroenterology. 2016;150:111324.e5. [DOI] [PubMed]
    Choi IJ, Kook MC, Kim YI, Cho SJ, Lee JY, Kim CG, et al. Helicobacter pylori therapy for the prevention of metachronous gastric cancer. N Engl J Med. 2018;378:108595. [DOI] [PubMed]
    Fukase K, Kato M, Kikuchi S, Inoue K, Uemura N, Okamoto S, et al. Effect of eradication of Helicobacter pylori on incidence of metachronous gastric carcinoma after endoscopic resection of early gastric cancer: an open-label, randomised controlled trial. Lancet. 2008;372:3927. [DOI] [PubMed]
    Zhao B, Zhang J, Mei D, Luo R, Lu H, Xu H, et al. Does Helicobacter pylori eradication reduce the incidence of metachronous gastric cancer after curative endoscopic resection of early gastric cancer: a systematic review and meta-analysis. J Clin Gastroenterol. 2020;54:23541. [DOI] [PubMed]
    Choi IJ, Kim CG, Lee JY, Kim YI, Kook MC, Park B, et al. Family history of gastric cancer and Helicobacter pylori treatment. N Engl J Med. 2020;382:42736. [DOI] [PubMed]
    Díaz P, Valenzuela Valderrama M, Bravo J, Quest AFG. Helicobacter pylori and gastric cancer: adaptive cellular mechanisms involved in disease progression. Front Microbiol. 2018;9:5. [DOI] [PubMed] [PMC]
    Sugano K, Tack J, Kuipers EJ, Graham DY, El-Omar EM, Miura S, et al. Kyoto global consensus report on Helicobacter pylori gastritis. Gut. 2015;64:135367. [DOI] [PubMed] [PMC]
    Malfertheiner P, Megraud F, O’Morain CA, Gisbert JP, Kuipers EJ, Axon AT, et al. Management of Helicobacter pylori infection-the Maastricht V/Florence Consensus Report. Gut. 2017;66:630. [DOI] [PubMed]
    Chey WD, Leontiadis GI, Howden CW, Moss SF. ACG Clinical Guideline: treatment of Helicobacter pylori infection. Am J Gastroenterol. 2017;112:21239. [DOI] [PubMed]
    Ushijima T, Hattori N. Molecular pathways: involvement of Helicobacter pylori-triggered inflammation in the formation of an epigenetic field defect, and its usefulness as cancer risk and exposure markers. Clin Cancer Res. 2012;18:9239. [DOI] [PubMed]
    Zabaleta J. MicroRNA: a bridge from H. pylori infection to gastritis and gastric cancer development. Front Genet. 2012;3:294. [DOI] [PubMed] [PMC]
    Take S, Mizuno M, Ishiki K, Kusumoto C, Imada T, Hamada F, et al. Risk of gastric cancer in the second decade of follow-up after Helicobacter pylori eradication. J Gastroenterol. 2020;55:2818. [DOI] [PubMed] [PMC]
    Lahner E, Carabotti M, Annibale B. Treatment of Helicobacter pylori infection in atrophic gastritis. World J Gastroenterol. 2018;24:237380. [DOI] [PubMed] [PMC]
    Rugge M, Genta RM. Staging and grading of chronic gastritis. Hum Pathol. 2005;36:22833. [DOI] [PubMed]
    Rugge M, Correa P, Di Mario F, El-Omar E, Fiocca R, Geboes K, et al. OLGA staging for gastritis: a tutorial. Dig Liver Dis. 2008;40:6508. [DOI] [PubMed]
    Kimura K, Satoh K, Ido K, Taniguchi Y, Takimoto T, Takemoto T. Gastritis in the Japanese stomach. Scand J Gastroenterol Suppl. 1996;214:1720. [DOI] [PubMed]
    Wang J, Xu L, Shi R, Huang X, Li SW, Huang Z, et al. Gastric atrophy and intestinal metaplasia before and after Helicobacter pylori eradication: a meta-analysis. Digestion. 2011;83:25360. [DOI] [PubMed]
    Rokkas T, Pistiolas D, Sechopoulos P, Robotis I, Margantinis G. The long-term impact of Helicobacter pylori eradication on gastric histology: a systematic review and meta-analysis. Helicobacter. 2007;12:328. [DOI] [PubMed]
    Hwang YJ, Kim N, Lee HS, Lee JB, Choi YJ, Yoon H, et al. Reversibility of atrophic gastritis and intestinal metaplasia after Helicobacter pylori eradication - a prospective study for up to 10 years. Aliment Pharmacol Ther. 2018;47:38090. [DOI] [PubMed]
    Wang T, Girgis S, Chang HJ, Assi A, Fagan-Garcia K, Cromarty T, et al. Changes in gastric pathology after H. pylori treatment in community-driven research aimed at gastric cancer prevention. Cancers (Basel). 2023;15:3950. [DOI] [PubMed] [PMC]
    Hu Y, Wan JH, Li XY, Zhu Y, Graham DY, Lu NH. Systematic review with meta-analysis: the global recurrence rate of Helicobacter pylori. Aliment Pharmacol Ther. 2017;46:7739. [DOI] [PubMed]
    Yan TL, Hu QD, Zhang Q, Li YM, Liang TB. National rates of Helicobacter pylori recurrence are significantly and inversely correlated with human development index. Aliment Pharmacol Ther. 2013;37:9638. [DOI] [PubMed]
    Nolen LD, Vindigni SM, Parsonnet J; Symposium leaders. Combating gastric cancer in Alaska native people: an expert and community symposium. Gastroenterology. 2020;158:1197201. [DOI] [PubMed] [PMC]
    Hildebrand P, Bardhan P, Rossi L, Parvin S, Rahman A, Arefin MS, et al. Recrudescence and reinfection with Helicobacter pylori after eradication therapy in Bangladeshi adults. Gastroenterology. 2001;121:7928. [DOI] [PubMed]
    Wheeldon TU, Hoang TT, Phung DC, Björkman A, Granström M, Sörberg M. Long-term follow-up of Helicobacter pylori eradication therapy in Vietnam: reinfection and clinical outcome. Aliment Pharmacol Ther. 2005;21:104753. [DOI] [PubMed]
    Take S, Mizuno M, Ishiki K, Imada T, Okuno T, Yoshida T, et al. Reinfection rate of Helicobacter pylori after eradication treatment: a long-term prospective study in Japan. J Gastroenterol. 2012;47:6416. [DOI] [PubMed]
    Ailloud F, Didelot X, Woltemate S, Pfaffinger G, Overmann J, Bader RC, et al. Within-host evolution of Helicobacter pylori shaped by niche-specific adaptation, intragastric migrations and selective sweeps. Nat Commun. 2019;10:2273. [DOI] [PubMed] [PMC]
    You WC, Brown LM, Zhang L, Li JY, Jin ML, Chang YS, et al. Randomized double-blind factorial trial of three treatments to reduce the prevalence of precancerous gastric lesions. J Natl Cancer Inst. 2006;98:97483. [DOI] [PubMed]
    Fan F, Wang Z, Li B, Zhang H. Effects of eradicating Helicobacter pylori on metachronous gastric cancer prevention: a systematic review and meta-analysis. J Eval Clin Pract. 2020;26:30815. [DOI] [PubMed]
    Manfredi M, Gismondi P, Iuliano S. Is Helicobacter pylori anyway pathogen in children? Inquiry. 2023;60:469580231154650. [DOI] [PubMed] [PMC]
    Marginean CM, Cioboata R, Olteanu M, Vasile CM, Popescu M, Popescu AIS, et al. The importance of accurate early diagnosis and eradication in Helicobacter pylori infection: pictorial summary review in children and adults. Antibiotics (Basel). 2022;12:60. [DOI] [PubMed] [PMC]
    Cifuentes SG, Prado MB, Fornasini M, Cohen H, Baldeón ME, Cárdenas PA. Saccharomyces boulardii CNCM I-745 supplementation modifies the fecal resistome during Helicobacter pylori eradication therapy. Helicobacter. 2022;27:e12870. [DOI] [PubMed]
    Zhang M, Zhang C, Zhao J, Zhang H, Zhai Q, Chen W. Meta-analysis of the efficacy of probiotic-supplemented therapy on the eradication of H. pylori and incidence of therapy-associated side effects. Microb Pathog. 2020;147:104403. [DOI] [PubMed]
    Nabavi-Rad A, Sadeghi A, Asadzadeh Aghdaei H, Yadegar A, Smith SM, Zali MR. The double-edged sword of probiotic supplementation on gut microbiota structure in Helicobacter pylori management. Gut Microbes. 2022;14:2108655. [DOI] [PubMed] [PMC]
    Du Y, Zhu H, Liu J, Li J, Chang X, Zhou L, et al. Consensus on eradication of Helicobacter pylori and prevention and control of gastric cancer in China (2019, Shanghai). J Gastroenterol Hepatol. 2020;35:6249. [DOI] [PubMed]
    El-Serag HB, Kao JY, Kanwal F, Gilger M, LoVecchio F, Moss SF, et al. Houston consensus conference on testing for Helicobacter pylori infection in the United States. Clin Gastroenterol Hepatol. 2018;16:9921002. [DOI] [PubMed] [PMC]
    Gupta S, Li D, El Serag HB, Davitkov P, Altayar O, Sultan S, et al. AGA Clinical practice guidelines on management of gastric intestinal metaplasia. Gastroenterology. 2020;158:693702. [DOI] [PubMed] [PMC]
    Hung KW, Knotts RM, Faye AS, Pont AR, Lebwohl B, Abrams JA, et al. Factors associated with adherence to Helicobacter pylori testing during hospitalization for bleeding peptic ulcer disease. Clin Gastroenterol Hepatol. 2020;18:10918. [DOI] [PubMed]
    Mortimer D, Segal L. Comparing the incomparable? A systematic review of competing techniques for converting descriptive measures of health status into QALY-weights. Med Decis Making. 2008;28:6689. [DOI] [PubMed]
    Griebsch I, Coast J, Brown J. Quality-adjusted life-years lack quality in pediatric care: a critical review of published cost-utility studies in child health. Pediatrics. 2005;115:e60014. [DOI] [PubMed]
    Paulden M. Calculating and interpreting ICERs and net benefit. Pharmacoeconomics. 2020;38:785807. [DOI] [PubMed]
    Høgh MB, Kronborg C, Hansen JM, Schaffalitzky de Muckadell OB. The cost effectiveness of Helicobacter pylori population screening—economic evaluation alongside a randomised controlled trial with 13-year follow-up. Aliment Pharmacol Ther. 2019;49:101325. [DOI] [PubMed]
    Chen Q, Liang X, Long X, Yu L, Liu W, Lu H. Cost-effectiveness analysis of screen-and-treat strategy in asymptomatic Chinese for preventing Helicobacter pylori-associated diseases. Helicobacter. 2019;24:e12563. [DOI] [PubMed]
    Han Y, Yan T, Ma H, Yao X, Lu C, Li Y, et al. Cost-effectiveness analysis of Helicobacter pylori eradication therapy for prevention of gastric cancer: a Markov model. Dig Dis Sci. 2020;65:167988. [DOI] [PubMed]
    Kakiuchi T, Matsuo M, Endo H, Nakayama A, Sato K, Takamori A, et al. A Helicobacter pylori screening and treatment program to eliminate gastric cancer among junior high school students in Saga Prefecture: a preliminary report. J Gastroenterol. 2019;54:699707. [DOI] [PubMed]
    Sarmasti M, Khoshbaten M, Khalili F, Yousefi M. Cost-effectiveness of screening Helicobacter pylori for gastric cancer prevention: a systematic review. J Gastrointest Cancer. 2022;53:1093103. [DOI] [PubMed]
    Feng T, Zheng Z, Xu J, Cao P, Gao S, Yu X. Cost-effectiveness analysis of the Helicobacter pylori screening programme in an asymptomatic population in China. Int J Environ Res Public Health. 2022;19:9986. [DOI] [PubMed] [PMC]
    Kowada A. A population-based Helicobacter pylori eradication strategy is more cost-effective than endoscopic screening. Dig Dis Sci. 2023;68:173546. [DOI] [PubMed] [PMC]
    Kowada A. Endoscopy is cost-effective for gastric cancer screening after successful Helicobacter pylori eradication. Dig Dis Sci. 2021;66:42206. [DOI] [PubMed]
    Hsieh YY, Tung SY, Pan HY, Yen CW, Xu HW, Lin YJ, et al. Increased abundance of Clostridium and Fusobacterium in gastric microbiota of patients with gastric cancer in Taiwan. Sci Rep. 2018;8:158. [DOI] [PubMed] [PMC]
    Liu X, Shao L, Liu X, Ji F, Mei Y, Cheng Y, et al. Alterations of gastric mucosal microbiota across different stomach microhabitats in a cohort of 276 patients with gastric cancer. EBioMedicine. 2019;40:33648. [DOI] [PubMed] [PMC]
    Rodriguez RM, Hernandez BY, Menor M, Deng Y, Khadka VS. The landscape of bacterial presence in tumor and adjacent normal tissue across 9 major cancer types using TCGA exome sequencing. Comput Struct Biotechnol J. 2020;18:63141. [DOI] [PubMed] [PMC]
    Vasapolli R, Schütte K, Schulz C, Vital M, Schomburg D, Pieper DH, et al. Analysis of transcriptionally active bacteria throughout the gastrointestinal tract of healthy individuals. Gastroenterology. 2019;157:108192.e3. [DOI] [PubMed]
    Chen CC, Liou JM, Lee YC, Hong TC, El-Omar EM, Wu MS. The interplay between Helicobacter pylori and gastrointestinal microbiota. Gut Microbes. 2021;13:122. [DOI] [PubMed] [PMC]
    Llorca L, Pérez-Pérez G, Urruzuno P, Martinez MJ, Iizumi T, Gao Z, et al. Characterization of the gastric microbiota in a pediatric population according to Helicobacter pylori status. Pediatr Infect Dis J. 2017;36:1738. [DOI] [PubMed]
    Miftahussurur M, Waskito LA, El-Serag HB, Ajami NJ, Nusi IA, Syam AF, et al. Gastric microbiota and Helicobacter pylori in Indonesian population. Helicobacter. 2020;25:e12695. [DOI] [PubMed]
    Wang D, Zhang T, Lu Y, Wang C, Wu Y, Li J, et al. Helicobacter pylori infection affects the human gastric microbiome, as revealed by metagenomic sequencing. FEBS Open Bio. 2022;12:118896. [DOI] [PubMed] [PMC]
    Lofgren JL, Whary MT, Ge Z, Muthupalani S, Taylor NS, Mobley M, et al. Lack of commensal flora in Helicobacter pylori-infected INS-GAS mice reduces gastritis and delays intraepithelial neoplasia. Gastroenterology. 2011;140:21020.e4. [DOI] [PubMed] [PMC]
    Lertpiriyapong K, Whary MT, Muthupalani S, Lofgren JL, Gamazon ER, Feng Y, et al. Gastric colonisation with a restricted commensal microbiota replicates the promotion of neoplastic lesions by diverse intestinal microbiota in the Helicobacter pylori INS-GAS mouse model of gastric carcinogenesis. Gut. 2014;63:5463. [DOI] [PubMed] [PMC]
    Ferreira RM, Pereira-Marques J, Pinto-Ribeiro I, Costa JL, Carneiro F, Machado JC, et al. Gastric microbial community profiling reveals a dysbiotic cancer-associated microbiota. Gut. 2018;67:22636. [DOI] [PubMed] [PMC]
    Coker OO, Dai Z, Nie Y, Zhao G, Cao L, Nakatsu G, et al. Mucosal microbiome dysbiosis in gastric carcinogenesis. Gut. 2018;67:102432. [DOI] [PubMed] [PMC]
    Hou L, El-Omar EM, Chen J, Grillo P, Rabkin CS, Baccarelli A, et al. Polymorphisms in Th1-type cell-mediated response genes and risk of gastric cancer. Carcinogenesis. 2007;28:11823. [DOI] [PubMed]
    Companioni O, Bonet C, Muñoz X, Weiderpass E, Panico S, Tumino R, et al. Polymorphisms of Helicobacter pylori signaling pathway genes and gastric cancer risk in the European prospective investigation into cancer-eurgast cohort. Int J Cancer. 2014;134:92101. [DOI] [PubMed]
    Malfertheiner P, Sipponen P, Naumann M, Moayyedi P, Mégraud F, Xiao SD, et al. Helicobacter pylori eradication has the potential to prevent gastric cancer: a state-of-the-art critique. Am J Gastroenterol. 2005;100:210015. [DOI] [PubMed]
    Sung JJY, Coker OO, Chu E, Szeto CH, Luk STY, Lau HCH, et al. Gastric microbes associated with gastric inflammation, atrophy and intestinal metaplasia 1 year after Helicobacter pylori eradication. Gut. 2020;69:157280. [DOI] [PubMed] [PMC]
    Niu ZY, Li SZ, Shi YY, Xue Y. Effect of gastric microbiota on quadruple Helicobacter pylori eradication therapy containing bismuth. World J Gastroenterol. 2021;27:391324. [DOI] [PubMed] [PMC]
    Schulz C, Schütte K, Malfertheiner P. Helicobacter pylori and other gastric microbiota in gastroduodenal pathologies. Dig Dis. 2016;34:2106. [DOI] [PubMed]
    Abrams JA, Gonsalves L, Neugut AI. Diverging trends in the incidence of reflux-related and Helicobacter pylori-related gastric cardia cancer. J Clin Gastroenterol. 2013;47:3227. [DOI] [PubMed] [PMC]
    Wang L, Zhou J, Xin Y, Geng C, Tian Z, Yu X, et al. Bacterial overgrowth and diversification of microbiota in gastric cancer. Eur J Gastroenterol Hepatol. 2016;28:2616. [DOI] [PubMed] [PMC]
    Liu X, Rong Z, Shou C. Mycoplasma hyorhinis infection promotes gastric cancer cell motility via β-catenin signaling. Cancer Med. 2019;8:530112. [DOI] [PMC]
    Miao R, Wan C, Wang Z. The relationship of gastric microbiota and Helicobacter pylori infection in pediatrics population. Helicobacter. 2020;25:e12676. [DOI] [PubMed]
    Zheng W, Miao J, Luo L, Long G, Chen B, Shu X, et al. The effects of Helicobacter pylori infection on microbiota associated with gastric mucosa and immune factors in children. Front Immunol. 2021;12:625586. [DOI] [PubMed] [PMC]
    Frost F, Kacprowski T, Rühlemann M, Bang C, Franke A, Zimmermann K, et al. Helicobacter pylori infection associates with fecal microbiota composition and diversity. Sci Rep. 2019;9:20100. [DOI] [PubMed] [PMC]
    Ramirez J, Guarner F, Bustos Fernandez L, Maruy A, Sdepanian VL, Cohen H. Antibiotics as major disruptors of gut microbiota. Front Cell Infect Microbiol. 2020;10:572912. [DOI] [PubMed] [PMC]
    Dash NR, Khoder G, Nada AM, Al Bataineh MT. Exploring the impact of Helicobacter pylori on gut microbiome composition. PLoS One. 2019;14:e0218274. [DOI] [PubMed] [PMC]
    Wang D, Li Y, Zhong H, Ding Q, Lin Y, Tang S, et al. Alterations in the human gut microbiome associated with Helicobacter pylori infection. FEBS Open Bio. 2019;9:155260. [DOI] [PubMed] [PMC]
    Jakobsson HE, Jernberg C, Andersson AF, Sjölund-Karlsson M, Jansson JK, Engstrand L. Short-term antibiotic treatment has differing long-term impacts on the human throat and gut microbiome. PLoS One. 2010;5:e9836. [DOI] [PubMed] [PMC]
    Chen L, Xu W, Lee A, He J, Huang B, Zheng W, et al. The impact of Helicobacter pylori infection, eradication therapy and probiotic supplementation on gut microenvironment homeostasis: an open-label, randomized clinical trial. EBioMedicine. 2018;35:8796. [DOI] [PubMed] [PMC]
    Fiorani M, Tohumcu E, Del Vecchio LE, Porcari S, Cammarota G, Gasbarrini A, et al. The influence of Helicobacter pylori on human gastric and gut microbiota. Antibiotics (Basel). 2023;12:765. [DOI] [PubMed] [PMC]
    de Assumpção PP, Araújo TMT, de Assumpção PB, Barra WF, Khayat AS, Assumpção CB, et al. Suicide journey of H. pylori through gastric carcinogenesis: the role of non-H. pylori microbiome and potential consequences for clinical practice. Eur J Clin Microbiol Infect Dis. 2019;38:15917. [DOI] [PubMed]
    Liatsos C, Papaefthymiou A, Kyriakos N, Galanopoulos M, Doulberis M, Giakoumis M, et al. Helicobacter pylori, gastric microbiota and gastric cancer relationship: unrolling the tangle. World J Gastrointest Oncol. 2022;14:95972. [DOI] [PubMed] [PMC]
    Bakhti SZ, Latifi-Navid S. Interplay and cooperation of Helicobacter pylori and gut microbiota in gastric carcinogenesis. BMC Microbiol. 2021;21:258. [DOI] [PubMed] [PMC]
    Guo Y, Zhang Y, Gerhard M, Gao JJ, Mejias-Luque R, Zhang L, et al. Effect of Helicobacter pylori on gastrointestinal microbiota: a population-based study in Linqu, a high-risk area of gastric cancer. Gut. 2020;69:1598607. [DOI] [PubMed] [PMC]
    Guo Y, Cao XS, Zhou MG, Yu B. Gastric microbiota in gastric cancer: different roles of Helicobacter pylori and other microbes. Front Cell Infect Microbiol. 2023;12:1105811. [DOI] [PubMed] [PMC]
    Cover TL, Blaser MJ. Helicobacter pylori in health and disease. Gastroenterology. 2009;136:186373. [DOI] [PubMed] [PMC]
    Chen Y, Blaser MJ. Helicobacter pylori colonization is inversely associated with childhood asthma. J Infect Dis. 2008;198:55360. [DOI] [PubMed] [PMC]
    Amedei A, Codolo G, Del Prete G, de Bernard M, D’Elios MM. The effect of Helicobacter pylori on asthma and allergy. J Asthma Allergy. 2010;3:13947. [DOI] [PubMed] [PMC]
    Liou JM, Lee YC, El-Omar EM, Wu MS. Efficacy and long-term safety of H. pylori eradication for gastric cancer prevention. Cancers (Basel). 2019;11:593. [DOI] [PubMed] [PMC]
    Liou JM, Lee YC, Wu MS. Treatment of Helicobacter pylori infection and its long-term impacts on gut microbiota. J Gastroenterol Hepatol. 2020;35:110716. [DOI] [PubMed]
    Medakina I, Tsapkova L, Polyakova V, Nikolaev S, Yanova T, Dekhnich N, et al. Helicobacter pylori antibiotic resistance: molecular basis and diagnostic methods. Int J Mol Sci. 2023;24:9433. [DOI] [PubMed] [PMC]
    Megraud F, Bruyndonckx R, Coenen S, Wittkop L, Huang TD, Hoebeke M, et al. Helicobacter pylori resistance to antibiotics in Europe in 2018 and its relationship to antibiotic consumption in the community. Gut. 2021;70:181522. [DOI] [PubMed]
    Savoldi A, Carrara E, Graham DY, Conti M, Tacconelli E. Prevalence of antibiotic resistance in Helicobacter pylori: a systematic review and meta-analysis in World Health Organization regions. Gastroenterology. 2018;155:137282.e17. [DOI] [PubMed] [PMC]
    Liu Y, Wang S, Yang F, Chi W, Ding L, Liu T, et al. Antimicrobial resistance patterns and genetic elements associated with the antibiotic resistance of Helicobacter pylori strains from Shanghai. Gut Pathog. 2022;14:14. [DOI] [PubMed] [PMC]
    Cho JH, Jin SY. Current guidelines for Helicobacter pylori treatment in East Asia 2022: differences among China, Japan, and South Korea. World J Clin Cases. 2022;10:634959. [DOI] [PubMed] [PMC]
    Li J, Deng J, Wang Z, Li H, Wan C. Antibiotic resistance of Helicobacter pylori strains isolated from pediatric patients in Southwest China. Front Microbiol. 2021;11:621791. [DOI] [PubMed] [PMC]
    Shu X, Ye D, Hu C, Peng K, Zhao H, Li H, et al. Alarming antibiotics resistance of Helicobacter pylori from children in Southeast China over 6 years. Sci Rep. 2022;12:17754. [DOI] [PubMed] [PMC]
    Karvelas A, Martinez-Gonzalez B, Papadopoulos VP, Panopoulou M, Sgouras D, Mimidis K. Real-time PCR detection of Helicobacter pylori clarithromycin resistance in Thrace, Greece. Hippokratia. 2021;25:515. [PubMed] [PMC]
    Lee YC, Dore MP, Graham DY. Diagnosis and treatment of Helicobacter pylori infection. Annu Rev Med. 2022;73:18395. [DOI] [PubMed]
    Blaser MJ. Helicobacter pylori and gastric diseases. BMJ. 1998;316:150710. [DOI] [PubMed] [PMC]
    Reshetnyak VI, Burmistrov AI, Maev IV. Helicobacter pylori: commensal, symbiont or pathogen? World J Gastroenterol. 2021;27:54560. [DOI] [PubMed] [PMC]
    Kononova S, Litvinova E, Vakhitov T, Skalinskaya M, Sitkin S. Acceptive immunity: the role of fucosylated glycans in human host–microbiome interactions. Int J Mol Sci. 2021;22:3854. [DOI] [PubMed] [PMC]
    Goto Y, Uematsu S, Kiyono H. Epithelial glycosylation in gut homeostasis and inflammation. Nat Immunol. 2016;17:124451. [DOI] [PubMed]
    Bravo D, Hoare A, Soto C, Valenzuela MA, Quest AF. Helicobacter pylori in human health and disease: mechanisms for local gastric and systemic effects. World J Gastroenterol. 2018;24:307189. [DOI] [PubMed] [PMC]
    Sitkin S, Lazebnik L, Avalueva E, Kononova S, Vakhitov T. Gastrointestinal microbiome and Helicobacter pylori: eradicate, leave it as it is, or take a personalized benefit-risk approach? World J Gastroenterol. 2022;28:76674. [DOI] [PubMed] [PMC]
    Lopetuso LR, Napoli M, Rizzatti G, Scaldaferri F, Franceschi F, Gasbarrini A. Considering gut microbiota disturbance in the management of Helicobacter pylori infection. Expert Rev Gastroenterol Hepatol. 2018;12:899906. [DOI] [PubMed]
    Shin CM, Kim N, Park JH, Lee DH. Changes in gastric corpus microbiota with age and after Helicobacter pylori eradication: a long-term follow-up study. Front Microbiol. 2021;11:621879. [DOI] [PubMed] [PMC]
    Gunathilake M, Lee J, Choi IJ, Kim YI, Kim J. Association between bacteria other than Helicobacter pylori and the risk of gastric cancer. Helicobacter. 2021;26:e12836. [DOI] [PubMed]
    Hsu PI, Pan CY, Kao JY, Tsay FW, Peng NJ, Kao SS, et al. Helicobacter pylori eradication with bismuth quadruple therapy leads to dysbiosis of gut microbiota with an increased relative abundance of Proteobacteria and decreased relative abundances of Bacteroidetes and Actinobacteria. Helicobacter. 2018;23:e12498. [DOI] [PubMed]
    Enemchukwu CU, Ben-Faras H, Gialanella P, Szymczak WA, Nosanchuk JD, Madaline TF. Butyricimonas virosa bacteraemia and bowel disease: case report and review. New Microbes New Infect. 2016;13:346. [DOI] [PubMed] [PMC]
    Zhou C, Zhao H, Xiao XY, Chen BD, Guo RJ, Wang Q, et al. Metagenomic profiling of the pro-inflammatory gut microbiota in ankylosing spondylitis. J Autoimmun. 2020;107:102360. [DOI] [PubMed]
    Liou JM, Chen CC, Chang CM, Fang YJ, Bair MJ, Chen PY, et al.; Taiwan Gastrointestinal Disease and Helicobacter Consortium. Long-term changes of gut microbiota, antibiotic resistance, and metabolic parameters after Helicobacter pylori eradication: a multicentre, open-label, randomised trial. Lancet Infect Dis. 2019;19:110920. [DOI] [PubMed]
    Lane JA, Murray LJ, Harvey IM, Donovan JL, Nair P, Harvey RF. Randomised clinical trial: Helicobacter pylori eradication is associated with a significantly increased body mass index in a placebo-controlled study. Aliment Pharmacol Ther. 2011;33:9229. [DOI] [PubMed]
    Francois F, Roper J, Joseph N, Pei Z, Chhada A, Shak JR, et al. The effect of H. pylori eradication on meal-associated changes in plasma ghrelin and leptin. BMC Gastroenterol. 2011;11:37. [DOI] [PubMed] [PMC]
    Martín-Núñez GM, Cornejo-Pareja I, Clemente-Postigo M, Tinahones FJ, Moreno-Indias I. Helicobacter pylori eradication therapy affect the gut microbiota and ghrelin levels. Front Med (Lausanne). 2021;8:712908. [DOI] [PubMed] [PMC]
    Martin-Nuñez GM, Cornejo-Pareja I, Clemente-Postigo M, Tinahones FJ. Gut microbiota: the missing link between Helicobacter pylori infection and metabolic disorders? Front Endocrinol (Lausanne). 2021;12:639856. [DOI] [PubMed] [PMC]
    Papamichael K, Konstantopoulos P, Mantzaris GJ. Helicobacter pylori infection and inflammatory bowel disease: is there a link? World J Gastroenterol. 2014;20:637485. [DOI] [PubMed] [PMC]
    Castaño-Rodríguez N, Kaakoush NO, Lee WS, Mitchell HM. Dual role of Helicobacter and Campylobacter species in IBD: a systematic review and meta-analysis. Gut. 2017;66:23549. [DOI] [PubMed]
    Engler DB, Leonardi I, Hartung ML, Kyburz A, Spath S, Becher B, et al. Helicobacter pylori-specific protection against inflammatory bowel disease requires the NLRP3 inflammasome and IL-18. Inflamm Bowel Dis. 2015;21:85461. [DOI] [PubMed]
    Zhou F, Zhu Q, Zheng PF, Feng YL. Association of fucosyltransferase 2 gene variant with inflammatory bowel diseases: a meta-analysis. Med Sci Monit. 2019;25:18492. [DOI] [PubMed] [PMC]
    Giampaoli O, Conta G, Calvani R, Miccheli A. Can the FUT2 non-secretor phenotype associated with gut microbiota increase the children susceptibility for type 1 diabetes? A mini review. Front Nutr. 2020;7:606171. [DOI] [PubMed] [PMC]
    Fan R, Han X, Gong Y, He L, Xue Z, Yang Y, et al. Alterations of fucosyltransferase genes and fucosylated glycans in gastric epithelial cells infected with Helicobacter pylori. Pathogens. 2021;10:168. [DOI] [PubMed] [PMC]
    Tang X, Wang W, Hong G, Duan C, Zhu S, Tian Y, et al. Gut microbiota-mediated lysophosphatidylcholine generation promotes colitis in intestinal epithelium-specific Fut2 deficiency. J Biomed Sci. 2021;28:20. [DOI] [PubMed] [PMC]
    Li Y, Jiang Y, Zhang L, Qian W, Hou X, Lin R. Exogenous l-fucose protects the intestinal mucosal barrier depending on upregulation of FUT2-mediated fucosylation of intestinal epithelial cells. FASEB J. 2021;35:e21699. [DOI] [PubMed]
    Axelrad JE, Cadwell KH, Colombel JF, Shah SC. Systematic review: gastrointestinal infection and incident inflammatory bowel disease. Aliment Pharmacol Ther. 2020;51:122232. [DOI] [PubMed] [PMC]
    Imawana RA, Smith DR, Goodson ML. The relationship between inflammatory bowel disease and Helicobacter pylori across East Asian, European and Mediterranean countries: a meta-analysis. Ann Gastroenterol. 2020;33:48594. [DOI] [PubMed] [PMC]
    Rokkas T, Gisbert JP, Niv Y, O’Morain C. The association between Helicobacter pylori infection and inflammatory bowel disease based on meta-analysis. United European Gastroenterol J. 2015;3:53950. [DOI] [PubMed] [PMC]
    Shirzad-Aski H, Besharat S, Kienesberger S, Sohrabi A, Roshandel G, Amiriani T, et al. Association between Helicobacter pylori colonization and inflammatory bowel disease: a systematic review and meta-analysis. J Clin Gastroenterol. 2021;55:38092. [DOI] [PubMed]
    Zhong Y, Zhang Z, Lin Y, Wu L. The relationship between Helicobacter pylori and inflammatory bowel disease. Arch Iran Med. 2021;24:31725. [DOI] [PubMed]
    Yap TW, Leow AH, Azmi AN, Callahan DL, Perez-Perez GI, Loke MF, et al. Global fecal and plasma metabolic dynamics related to Helicobacter pylori eradication. Front Microbiol. 2017;8:536. [DOI] [PubMed] [PMC]
    Malnick SD, Melzer E, Attali M, Duek G, Yahav J. Helicobacter pylori: friend or foe? World J Gastroenterol. 2014;20:897985. [DOI] [PubMed] [PMC]
    Miller AK, Williams SM. Helicobacter pylori infection causes both protective and deleterious effects in human health and disease. Genes Immun. 2021;22:21826. [DOI] [PubMed] [PMC]
    Anderson LA, Murphy SJ, Johnston BT, Watson RG, Ferguson HR, Bamford KB, et al. Relationship between Helicobacter pylori infection and gastric atrophy and the stages of the oesophageal inflammation, metaplasia, adenocarcinoma sequence: results from the FINBAR case-control study. Gut. 2008;57:7349. [DOI] [PubMed]
    Peek RM Jr, Blaser MJ. Helicobacter pylori and gastrointestinal tract adenocarcinomas. Nat Rev Cancer. 2002;2:2837. [DOI] [PubMed]
    Corley DA, Kubo A, Levin TR, Block G, Habel L, Zhao W, et al. Helicobacter pylori infection and the risk of Barrett’s oesophagus: a community-based study. Gut. 2008;57:72733. [DOI] [PubMed] [PMC]
    Wang Z, Shaheen NJ, Whiteman DC, Anderson LA, Vaughan TL, Corley DA, et al. Helicobacter pylori infection is associated with reduced risk of Barrett’s esophagus: an analysis of the Barrett’s and Esophageal Adenocarcinoma Consortium. Am J Gastroenterol. 2018;113:114855. [DOI] [PubMed]
    Deshpande NP, Riordan SM, Castaño-Rodríguez N, Wilkins MR, Kaakoush NO. Signatures within the esophageal microbiome are associated with host genetics, age, and disease. Microbiome. 2018;6:227. [DOI] [PubMed] [PMC]
    Amir I, Konikoff FM, Oppenheim M, Gophna U, Half EE. Gastric microbiota is altered in oesophagitis and Barrett’s oesophagus and further modified by proton pump inhibitors. Environ Microbiol. 2014;16:290514. [DOI] [PubMed]
    Doulberis M, Kountouras J, Rogler G. Reconsidering the “protective” hypothesis of Helicobacter pylori infection in eosinophilic esophagitis. Ann N Y Acad Sci. 2020;1481:5971. [DOI] [PubMed]
    Labenz J, Blum AL, Bayerdörffer E, Meining A, Stolte M, Börsch G. Curing Helicobacter pylori infection in patients with duodenal ulcer may provoke reflux esophagitis. Gastroenterology. 1997;112:14427. [DOI] [PubMed]
    Xie FJ, Zhang YP, Zheng QQ, Jin HC, Wang FL, Chen M, et al. Helicobacter pylori infection and esophageal cancer risk: an updated meta-analysis. World J Gastroenterol. 2013;19:6098107. [DOI] [PubMed] [PMC]
    Del Vecchio LE, Fiorani M, Tohumcu E, Porcari S, Cammarota G. Review: Helicobacter pylori and extragastric diseases. Microb Health Dis. 2022;4:e719. [DOI] [PubMed]
    Umar M, Upadhyay R, Mittal B. PLCE1 rs2274223 A>G polymorphism and cancer risk: a meta-analysis. Tumour Biol. 2013;34:353744. [DOI] [PubMed]
    Rokkas T, Pistiolas D, Sechopoulos P, Robotis I, Margantinis G. Relationship between Helicobacter pylori infection and esophageal neoplasia: a meta-analysis. Clin Gastroenterol Hepatol. 2007;5:14137.e2. [DOI] [PubMed]
    Usui G, Sato H, Shinozaki T, Jinno T, Fujibayashi K, Ishii K, et al. Association between Helicobacter pylori infection and short-segment/long-segment Barrett’s esophagus in a Japanese population: a large cross-sectional study. J Clin Gastroenterol. 2020;54:43944. [DOI] [PubMed]
    Erőss B, Farkas N, Vincze Á, Tinusz B, Szapáry L, Garami A, et al. Helicobacter pylori infection reduces the risk of Barrett’s esophagus: a meta-analysis and systematic review. Helicobacter. 2018;23:e12504. [DOI] [PubMed] [PMC]
    Fischbach LA, Graham DY, Kramer JR, Rugge M, Verstovsek G, Parente P, et al. Association between Helicobacter pylori and Barrett’s esophagus: a case–control study. Am J Gastroenterol. 2014;109:35768. [DOI] [PubMed] [PMC]
    Du YL, Duan RQ, Duan LP. Helicobacter pylori infection is associated with reduced risk of Barrett’s esophagus: a meta-analysis and systematic review. BMC Gastroenterol. 2021;21:459. [DOI] [PubMed] [PMC]
    Fischbach LA, Nordenstedt H, Kramer JR, Gandhi S, Dick-Onuoha S, Lewis A, et al. The association between Barrett’s esophagus and Helicobacter pylori infection: a meta-analysis. Helicobacter. 2012;17:16375. [DOI] [PubMed] [PMC]
    Rubenstein JH, Inadomi JM, Scheiman J, Schoenfeld P, Appelman H, Zhang M, et al. Association between Helicobacter pylori and Barrett’s esophagus, erosive esophagitis, and gastroesophageal reflux symptoms. Clin Gastroenterol Hepatol. 2014;12:23945. [DOI] [PubMed] [PMC]
    Nie S, Chen T, Yang X, Huai P, Lu M. Association of Helicobacter pylori infection with esophageal adenocarcinoma and squamous cell carcinoma: a meta-analysis. Dis Esophagus. 2014;27:64553. [DOI] [PubMed]
    Doorakkers E, Lagergren J, Santoni G, Engstrand L, Brusselaers N. Helicobacter pylori eradication treatment and the risk of Barrett’s esophagus and esophageal adenocarcinoma. Helicobacter. 2020;25:e12688. [DOI] [PubMed]
    Zamani M, Alizadeh-Tabari S, Hasanpour AH, Eusebi LH, Ford AC. Systematic review with meta-analysis: association of Helicobacter pylori infection with gastro-oesophageal reflux and its complications. Aliment Pharmacol Ther. 2021;54:98898. [DOI] [PubMed]
    Malfertheiner P, Megraud F, Rokkas T, Gisbert JP, Liou JM, Schulz C, et al. Management of Helicobacter pylori infection: the Maastricht VI/Florence consensus report. Gut. 2022;71:172462. [DOI] [PubMed]
    Kumar S, Metz DC, Ginsberg GG, Kaplan DE, Goldberg DS. Oesophageal and proximal gastric adenocarcinomas are rare after detection of Helicobacter pylori infection. Aliment Pharmacol Ther. 2020;51:7818. [DOI] [PubMed] [PMC]
    McCune A, Lane A, Murray L, Harvey I, Nair P, Donovan J, et al. Reduced risk of atopic disorders in adults with Helicobacter pylori infection. Eur J Gastroenterol Hepatol. 2003;15:63740. [DOI] [PubMed]
    Chen Y, Blaser MJ. Inverse associations of Helicobacter pylori with asthma and allergy. Arch Intern Med. 2007;167:8217. [DOI] [PubMed]
    Amberbir A, Medhin G, Erku W, Alem A, Simms R, Robinson K, et al. Effects of Helicobacter pylori, geohelminth infection and selected commensal bacteria on the risk of allergic disease and sensitization in 3-year-old Ethiopian children. Clin Exp Allergy. 2011;41:142230. [DOI] [PubMed]
    Amberbir A, Medhin G, Abegaz WE, Hanlon C, Robinson K, Fogarty A, et al. Exposure to Helicobacter pylori infection in early childhood and the risk of allergic disease and atopic sensitization: a longitudinal birth cohort study. Clin Exp Allergy. 2014;44:56371. [DOI] [PubMed] [PMC]
    Ness-Jensen E, Langhammer A, Hveem K, Lu Y. Helicobacter pylori in relation to asthma and allergy modified by abdominal obesity: The HUNT study in Norway. World Allergy Organ J. 2019;12:100035. [DOI] [PubMed] [PMC]
    Fouda EM, Kamel TB, Nabih ES, Abdelazem AA. Helicobacter pylori seropositivity protects against childhood asthma and inversely correlates to its clinical and functional severity. Allergol Immunopathol (Madr). 2018;46:7681. [DOI] [PubMed]
    Khamechian T, Movahedian AH, Ebrahimi Eskandari G, Heidarzadeh Arani M, Mohammadi A. Evaluation of the correlation between childhood asthma and Helicobacter pylori in Kashan. Jundishapur J Microbiol. 2015;8:e17842. [DOI] [PubMed] [PMC]
    Reibman J, Marmor M, Filner J, Fernandez-Beros ME, Rogers L, Perez-Perez GI, et al. Asthma is inversely associated with Helicobacter pylori status in an urban population. PLoS One. 2008;3:e4060. [DOI] [PubMed] [PMC]
    Koch KN, Hartung ML, Urban S, Kyburz A, Bahlmann AS, Lind J, et al. Helicobacter urease-induced activation of the TLR2/NLRP3/IL-18 axis protects against asthma. J Clin Invest. 2015;125:3297302. [DOI] [PubMed] [PMC]
    Tsigalou C, Konstantinidis TG, Cassimos D, Karvelas A, Grapsa A, Tsalkidis A, et al. Inverse association between Helicobacter pylori infection and childhood asthma in Greece: a case-control study. Germs. 2019;9:1827. [DOI] [PubMed] [PMC]
    Chen C, Xun P, Tsinovoi C, He K. Accumulated evidence on Helicobacter pylori infection and the risk of asthma: a meta-analysis. Ann Allergy Asthma Immunol. 2017;119:13745.e2. [DOI] [PubMed]
    Borbet TC, Zhang X, Müller A, Blaser MJ. The role of the changing human microbiome in the asthma pandemic. J Allergy Clin Immunol. 2019;144:145766. [DOI] [PubMed] [PMC]
    Arnold IC, Dehzad N, Reuter S, Martin H, Becher B, Taube C, et al. Helicobacter pylori infection prevents allergic asthma in mouse models through the induction of regulatory T cells. J Clin Invest. 2011;121:308893. [DOI] [PubMed] [PMC]
    Oertli M, Sundquist M, Hitzler I, Engler DB, Arnold IC, Reuter S, et al. DC-derived IL-18 drives Treg differentiation, murine Helicobacter pylori-specific immune tolerance, and asthma protection. J Clin Invest. 2012;122:108296. [DOI] [PubMed] [PMC]
    Zuo ZT, Ma Y, Sun Y, Bai CQ, Ling CH, Yuan FL. The protective effects of Helicobacter pylori infection on allergic asthma. Int Arch Allergy Immunol. 2021;182:5364. [DOI] [PubMed] [PMC]
    Kyburz A, Fallegger A, Zhang X, Altobelli A, Artola-Boran M, Borbet T, et al. Transmaternal Helicobacter pylori exposure reduces allergic airway inflammation in offspring through regulatory T cells. J Allergy Clin Immunol. 2019;143:1496512.e11. [DOI] [PubMed] [PMC]
    van Wijck Y, John-Schuster G, van Schadewijk A, van den Oever RL, Obieglo K, Hiemstra PS, et al. Extract of Helicobacter pylori ameliorates parameters of airway inflammation and goblet cell hyperplasia following repeated allergen exposure. Int Arch Allergy Immunol. 2019;180:19. [DOI] [PubMed]
    Reuter S, Raspe J, Uebner H, Contoyannis A, Pastille E, Westendorf AM, et al. Treatment with Helicobacter pylori-derived VacA attenuates allergic airway disease. Front Immunol. 2023;14:1092801. [DOI] [PubMed] [PMC]
    Engler DB, Reuter S, van Wijck Y, Urban S, Kyburz A, Maxeiner J, et al. Effective treatment of allergic airway inflammation with Helicobacter pylori immunomodulators requires BATF3-dependent dendritic cells and IL-10. Proc Natl Acad Sci U S A. 2014;111:118105. [DOI] [PubMed] [PMC]
    Altobelli A, Bauer M, Velez K, Cover TL, Müller A. Helicobacter pylori VacA targets myeloid cells in the gastric lamina propria to promote peripherally induced regulatory T-cell differentiation and persistent infection. mBio. 2019;10:e0026119. [DOI] [PubMed] [PMC]
    Peng Q, Qiu X, Zhang Z, Zhang S, Zhang Y, Liang Y, et al. PD-L1 on dendritic cells attenuates T cell activation and regulates response to immune checkpoint blockade. Nat Commun. 2020;11:4835. [DOI] [PubMed] [PMC]
    Rosskopf S, Jahn-Schmid B, Schmetterer KG, Zlabinger GJ, Steinberger P. PD-1 has a unique capacity to inhibit allergen-specific human CD4+ T cell responses. Sci Rep. 2018;8:13543. [DOI] [PubMed] [PMC]
    Manavalan JS, Rossi PC, Vlad G, Piazza F, Yarilina A, Cortesini R, et al. High expression of ILT3 and ILT4 is a general feature of tolerogenic dendritic cells. Transpl Immunol. 2003;11:24558. [DOI] [PubMed]
    den Hollander WJ, Sonnenschein-van der Voort AM, Holster IL, de Jongste JC, Jaddoe VW, Hofman A, et al. Helicobacter pylori in children with asthmatic conditions at school age, and their mothers. Aliment Pharmacol Ther. 2016;43:93343. [DOI] [PubMed] [PMC]
    Upala S, Sanguankeo A, Saleem SA, Jaruvongvanich V. Effects of Helicobacter pylori eradication on insulin resistance and metabolic parameters: a systematic review and meta-analysis. Eur J Gastroenterol Hepatol. 2017;29:1539. [DOI] [PubMed]
    Osawa H, Nakazato M, Date Y, Kita H, Ohnishi H, Ueno H, et al. Impaired production of gastric ghrelin in chronic gastritis associated with Helicobacter pylori. J Clin Endocrinol Metab. 2005;90:106. [DOI] [PubMed]
    Annagür A, Kendirli SG, Yilmaz M, Altintas DU, Inal A. Is there any relationship between asthma and asthma attack in children and atypical bacterial infections; Chlamydia pneumoniae, Mycoplasma pneumoniae and Helicobacter pylori. J Trop Pediatr. 2007;53:3138. [DOI] [PubMed]
    Fullerton D, Britton JR, Lewis SA, Pavord ID, McKeever TM, Fogarty AW. Helicobacter pylori and lung function, asthma, atopy and allergic disease—a population-based cross-sectional study in adults. Int J Epidemiol. 2009;38:41926. [DOI] [PubMed]
    Alvarez CS, Avilés-Santa ML, Freedman ND, Perreira KM, Garcia-Bedoya O, Kaplan RC, et al. Associations of Helicobacter pylori and hepatitis A seropositivity with asthma in the Hispanic Community Health Study/Study of Latinos (HCHS/SOL): addressing the hygiene hypothesis. Allergy Asthma Clin Immunol. 2021;17:120. [DOI] [PubMed] [PMC]
    Rostami-Nejad M, Javad Ehsani-Ardakani M, Assadzadeh H, Shahbazkhani B, Ierardi E, Losurdo G, et al. Pathological and clinical correlation between celiac disease and Helicobacter Pylori infection; a review of controversial reports. Middle East J Dig Dis. 2016;8:8592. [DOI] [PubMed] [PMC]
    Cârdei E, Moraru D, Trandafir L, Bozomitu L, Mihăilă D. Celiac disease associated with Helicobacter pylori infection. Rev Med Chir Soc Med Nat Iasi. 2003;107:6335. Romanian. [PubMed]
    Rothenbacher D, Blaser MJ, Bode G, Brenner H. Inverse relationship between gastric colonization of Helicobacter pylori and diarrheal illnesses in children: results of a population-based cross-sectional study. J Infect Dis. 2000;182:14469. [DOI] [PubMed]
    Bode G, Rothenbacher D, Brenner H. Helicobacter pylori colonization and diarrhoeal illness: results of a population-based cross-sectional study in adults. Eur J Epidemiol. 2001;17:8237. [DOI] [PubMed]
    Perry S, de Jong BC, Solnick JV, de la Luz Sanchez M, Yang S, Lin PL, et al. Infection with Helicobacter pylori is associated with protection against tuberculosis. PLoS One. 2010;5:e8804. [DOI] [PubMed] [PMC]
    Smith S, Fowora M, Pellicano R. Infections with Helicobacter pylori and challenges encountered in Africa. World J Gastroenterol. 2019;25:318395. [DOI] [PubMed] [PMC]
    Misra V, Pandey R, Misra SP, Dwivedi M. Helicobacter pylori and gastric cancer: Indian enigma. World J Gastroenterol. 2014;20:15039. [DOI] [PubMed] [PMC]
    Graham DY, Lu H, Yamaoka Y. African, Asian or Indian enigma, the East Asian Helicobacter pylori: facts or medical myths. J Dig Dis. 2009;10:7784. [DOI] [PubMed] [PMC]
    Lunet N, Barros H. Helicobacter pylori infection and gastric cancer: facing the enigmas. Int J Cancer. 2003;106:95360. [DOI] [PubMed]
    Herrero R, Heise K, Acevedo J, Cook P, Gonzalez C, Gahona J, et al. Regional variations in Helicobacter pylori infection, gastric atrophy and gastric cancer risk: the ENIGMA study in Chile. PLoS One. 2020;15:e0237515. [DOI] [PubMed] [PMC]
    Cavadas B, Leite M, Pedro N, Magalhães AC, Melo J, Correia M, et al. Shedding light on the African enigma: in vitro testing of Homo sapiens-Helicobacter pylori coevolution. Microorganisms. 2021;9:240. [DOI] [PubMed] [PMC]
    The EUROGAST Study Group. An international association between Helicobacter pylori infection and gastric cancer. Lancet. 1993;341:135962. [DOI] [PubMed]
    Apostolopoulos P, Vafiadis-Zouboulis I, Tzivras M, Kourtessas D, Katsilambros N, Archimandritis A. Helicobacter pylori (H pylori) infection in Greece: the changing prevalence during a ten-year period and its antigenic profile. BMC Gastroenterol. 2002;2:11. [DOI] [PubMed] [PMC]
    Laine L, Dhir V. Helicobacter pylori eradication does not worsen quality of life related to reflux symptoms: a prospective trial. Aliment Pharmacol Ther. 2002;16:11438. [DOI] [PubMed]
    Moayyedi P, Feltbower R, Brown J, Mason S, Mason J, Nathan J, et al. Effect of population screening and treatment for Helicobacter pylori on dyspepsia and quality of life in the community: a randomised controlled trial. Lancet. 2000;355:16659. [DOI] [PubMed]
    Bektas M, Soykan I, Altan M, Alkan M, Ozden A. The effect of Helicobacter pylori eradication on dyspeptic symptoms, acid reflux and quality of life in patients with functional dyspepsia. Eur J Intern Med. 2009;20:41923. [DOI] [PubMed]
    Buzás GM. Quality of life in patients with functional dyspepsia: Short- and long-term effect of Helicobacter pylori eradication with pantoprazole, amoxicillin, and clarithromycin or cisapride therapy: a prospective, parallel-group study. Curr Ther Res Clin Exp. 2006;67:30520. [DOI] [PubMed] [PMC]
    Mestrovic A, Bozic J, Vukojevic K, Tonkic A. Impact of different Helicobacter pylori eradication therapies on gastrointestinal symptoms. Medicina (Kaunas). 2021;57:803. [DOI] [PubMed] [PMC]
    Kabakambira JD, Hategeka C, Page C, Ntirenganya C, Dusabejambo V, Ndoli J, et al. Efficacy of Helicobacter pylori eradication regimens in Rwanda: a randomized controlled trial. BMC Gastroenterol. 2018;18:134. [DOI] [PubMed] [PMC]
    Bitwayiki R, Orikiiriza JT, Kateera F, Bihizimana P, Karenzi B, Kyamanywa P, et al. Dyspepsia prevalence and impact on quality of life among Rwandan healthcare workers: a cross-sectional survey. S Afr Med J. 2015;105:10649. [DOI] [PubMed]
    Menotti A, Kromhout D, Blackburn H, Fidanza F, Buzina R, Nissinen A. Food intake patterns and 25-year mortality from coronary heart disease: cross-cultural correlations in the Seven Countries Study. Eur J Epidemiol. 1999;15:50715. [DOI] [PubMed]
    Menotti A, Blackburn H, Kromhout D, Nissinen A, Adachi H, Lanti M. Cardiovascular risk factors as determinants of 25-year all-cause mortality in the seven countries study. Eur J Epidemiol. 2001;17:33746. [DOI] [PubMed]
    Menotti A, Puddu PE, Tolonen H, Kafatos A. Cardiovascular mortality in Northern and Southern European cohorts of the Seven Countries Study at 60-year follow-up. J Cardiovasc Med (Hagerstown). 2023;24:96104. [DOI] [PubMed]
    Trichopoulos D, Ouranos G, Day NE, Tzonou A, Manousos O, Papadimitriou C, et al. Diet and cancer of the stomach: a case-control study in Greece. Int J Cancer. 1985;36:2917. [PubMed]
    La Vecchia C, Negri E, Decarli A, D’Avanzo B, Franceschi S. A case-control study of diet and gastric cancer in northern Italy. Int J Cancer. 1987;40:4849. [DOI] [PubMed]
    Gonzalez CA, Lujan-Barroso L, Bueno-de-Mesquita HB, Jenab M, Duell EJ, Agudo A, et al. Fruit and vegetable intake and the risk of gastric adenocarcinoma: a reanalysis of the european prospective investigation into cancer and nutrition (EPIC-EURGAST) study after a longer follow-up. Int J Cancer. 2012;131:29109. [DOI] [PubMed]
    Russo A, Eboli M, Pizzetti P, Di Felice G, Ravagnani F, Spinelli P, et al. Determinants of Helicobacter pylori seroprevalence among Italian blood donors. Eur J Gastroenterol Hepatol. 1999;11:86773. [DOI] [PubMed]
    Boccia S, La Vecchia C. Dissecting causal components in gastric carcinogenesis. Eur J Cancer Prev. 2013;22:48991. [DOI] [PubMed]
    De Stefani E, Correa P, Boffetta P, Deneo-Pellegrini H, Ronco AL, Mendilaharsu M. Dietary patterns and risk of gastric cancer: a case-control study in Uruguay. Gastric Cancer. 2004;7:21120. [DOI] [PubMed]
    Campbell PT, Sloan M, Kreiger N. Dietary patterns and risk of incident gastric adenocarcinoma. Am J Epidemiol. 2008;167:295304. [DOI] [PubMed]
    Bertuccio P, Rosato V, Andreano A, Ferraroni M, Decarli A, Edefonti V, et al. Dietary patterns and gastric cancer risk: a systematic review and meta-analysis. Ann Oncol. 2013;24:14508. [DOI] [PubMed]
    Praud D, Bertuccio P, Bosetti C, Turati F, Ferraroni M, La Vecchia C. Adherence to the Mediterranean diet and gastric cancer risk in Italy. Int J Cancer. 2014;134:293541. [DOI] [PubMed]
    Schulpen M, Peeters PH, van den Brandt PA. Mediterranean diet adherence and risk of esophageal and gastric cancer subtypes in the Netherlands Cohort Study. Gastric Cancer. 2019;22:66374. [DOI] [PubMed] [PMC]
    Morze J, Danielewicz A, Przybyłowicz K, Zeng H, Hoffmann G, Schwingshackl L. An updated systematic review and meta-analysis on adherence to mediterranean diet and risk of cancer. Eur J Nutr. 2021;60:156186. [DOI] [PubMed] [PMC]
    Bai X, Li X, Ding S, Dai D. Adherence to the Mediterranean diet and risk of gastric cancer: a systematic review and meta-analysis. Nutrients. 2023;15:3826. [DOI] [PubMed] [PMC]
    Álvarez-Álvarez L, Vitelli-Storelli F, Rubín-García M, Aragonés N, Ardanaz E, Castaño-Vinyals G, et al. Relationship between the risk of gastric cancer and adherence to the Mediterranean diet according to different estimators. MCC—Spain study. Cancers (Basel). 2021;13:5281. [DOI] [PubMed] [PMC]
    Amiry F, Mousavi SM, Barekzai AM, Esmaillzadeh A. Adherence to the Mediterranean diet in relation to gastric cancer in Afghanistan. Front Nutr. 2022;9:830646. [DOI] [PubMed] [PMC]
    Vermorken AJM, Zhu J, Cui Y. Letter: Does Helicobacter pylori infection limit the health effects of the Mediterranean diet? Aliment Pharmacol Ther. 2020;52:9356. [DOI] [PubMed]
    Scrafford CG, Bi X, Multani JK, Murphy MM, Schmier JK, Barraj LM. Health economic evaluation modeling shows potential health care cost savings with increased conformance with healthy dietary patterns among adults in the United States. J Acad Nutr Diet. 2019;119:599616. [DOI] [PubMed]
    Ferro A, Peleteiro B, Malvezzi M, Bosetti C, Bertuccio P, Levi F, et al. Worldwide trends in gastric cancer mortality (1980–2011), with predictions to 2015, and incidence by subtype. Eur J Cancer. 2014;50:133044. [DOI] [PubMed]
    Praud D, Rota M, Pelucchi C, Bertuccio P, Rosso T, Galeone C, et al. Cigarette smoking and gastric cancer in the Stomach Cancer Pooling (StoP) Project. Eur J Cancer Prev. 2018;27:12433. [DOI] [PubMed]
    Bouras E, Tsilidis KK, Triggi M, Siargkas A, Chourdakis M, Haidich AB. Diet and risk of gastric cancer: an umbrella review. Nutrients. 2022;14:1764. [DOI] [PubMed] [PMC]
    Wu X, Chen L, Cheng J, Qian J, Fang Z, Wu J. Effect of dietary salt intake on risk of gastric cancer: a systematic review and meta-analysis of case-control studies. Nutrients. 2022;14:4260. [DOI] [PubMed] [PMC]
    Azizi N, Zangiabadian M, Seifi G, Davari A, Yekekhani E, Safavi-Naini SAA, et al. Gastric cancer risk in association with underweight, overweight, and obesity: a systematic review and meta-analysis. Cancers (Basel). 2023;15:2778. [DOI] [PubMed] [PMC]
    Liu SJ, Huang PD, Xu JM, Li Q, Xie JH, Wu WZ, et al. Diet and gastric cancer risk: an umbrella review of systematic reviews and meta-analyses of prospective cohort studies. J Cancer Res Clin Oncol. 2022;148:185568. [DOI] [PubMed]
    Li Y, Li X, Tan Z. An overview of traditional Chinese medicine therapy for Helicobacter pylori-related gastritis. Helicobacter. 2021;26:e12799. [DOI] [PubMed]
    Liu M, Zhong Y, Chen J, Liu Y, Tang C, Wang X, et al. Oral immunization of mice with a multivalent therapeutic subunit vaccine protects against Helicobacter pylori infection. Vaccine. 2020;38:303141. [DOI] [PubMed]
    Chen J, Zhong Y, Liu Y, Tang C, Zhang Y, Wei B, et al. Parenteral immunization with a cyclic guanosine monophosphate-adenosine monophosphate (cGAMP) adjuvanted Helicobacter pylori vaccine induces protective immunity against H. pylori infection in mice. Hum Vaccin Immunother. 2020;16:284954. [DOI] [PubMed] [PMC]
    Rokkas T, Filipe MI, Sladen GE. Detection of an increased incidence of early gastric cancer in patients with intestinal metaplasia type III who are closely followed up. Gut. 1991;32:11103. [DOI] [PubMed] [PMC]
    El-Zimaity HM, Ota H, Graham DY, Akamatsu T, Katsuyama T. Patterns of gastric atrophy in intestinal type gastric carcinoma. Cancer. 2002;94:142836. [DOI] [PubMed]
    Reis CA, David L, Correa P, Carneiro F, de Bolós C, Garcia E, et al. Intestinal metaplasia of human stomach displays distinct patterns of mucin (MUC1, MUC2, MUC5AC, and MUC6) expression. Cancer Res. 1999;59:10037. [PubMed]
    Battista S, Ambrosio MR, Limarzi F, Gallo G, Saragoni L. Molecular alterations in gastric preneoplastic lesions and early gastric cancer. Int J Mol Sci. 2021;22:6652. [DOI] [PubMed] [PMC]
    Schmidt PH, Lee JR, Joshi V, Playford RJ, Poulsom R, Wright NA, et al. Identification of a metaplastic cell lineage associated with human gastric adenocarcinoma. Lab Invest. 1999;79:63946. [PubMed]
    Goldenring JR, Nam KT, Wang TC, Mills JC, Wright NA. Spasmolytic polypeptide-expressing metaplasia and intestinal metaplasia: time for reevaluation of metaplasias and the origins of gastric cancer. Gastroenterology. 2010; 138:220710.e1. [DOI] [PubMed] [PMC]
    Li ML, Hong XX, Zhang WJ, Liang YZ, Cai TT, Xu YF, et al. Helicobacter pylori plays a key role in gastric adenocarcinoma induced by spasmolytic polypeptide-expressing metaplasia. World J Clin Cases. 2023;11:371424. [DOI] [PubMed] [PMC]
    Liu X, Ma Z, Deng Z, Yi Z, Tuo B, Li T, et al. Role of spasmolytic polypeptide-expressing metaplasia in gastric mucosal diseases. Am J Cancer Res. 2023;13:166781. [PubMed] [PMC]
    Goldenring JR, Mills JC. Cellular plasticity, reprogramming, and regeneration: metaplasia in the stomach and beyond. Gastroenterology. 2022;162:41530. [DOI] [PubMed] [PMC]
    el-Zimaity HM, Graham DY, al-Assi MT, Malaty H, Karttunen TJ, Graham DP, et al. Interobserver variation in the histopathological assessment of Helicobacter pylori gastritis. Hum Pathol. 1996;27:3541. [DOI] [PubMed]
    Offerhaus GJ, Price AB, Haot J, ten Kate FJ, Sipponen P, Fiocca R, et al. Observer agreement on the grading of gastric atrophy. Histopathology. 1999;34:3205. [DOI] [PubMed]
    den Hoed CM, Holster IL, Capelle LG, de Vries AC, den Hartog B, Ter Borg F, et al. Follow-up of premalignant lesions in patients at risk for progression to gastric cancer. Endoscopy. 2013;45:24956. [DOI] [PubMed]
    de Vries AC, van Grieken NC, Looman CW, Casparie MK, de Vries E, Meijer GA, et al. Gastric cancer risk in patients with premalignant gastric lesions: a nationwide cohort study in the Netherlands. Gastroenterology. 2008;134:94552. [DOI] [PubMed]
    Cheng HC, Yang YJ, Yang HB, Tsai YC, Chang WL, Wu CT, et al. Evolution of the Correa’s cascade steps: a long-term endoscopic surveillance among non-ulcer dyspepsia and gastric ulcer after H. pylori eradication. J Formos Med Assoc. 2023;122:40010. [DOI] [PubMed]
    Helicobacter and Cancer Collaborative Group. Gastric cancer and Helicobacter pylori: a combined analysis of 12 case control studies nested within prospective cohorts. Gut. 2001;49:34753. [DOI] [PubMed] [PMC]
    Poynard T, Munteanu M, Ratziu V, Benhamou Y, Di Martino V, Taieb J, et al. Truth survival in clinical research: an evidence-based requiem? Ann Intern Med. 2002;136:88895. [DOI] [PubMed]
    Koretz RL, Poynard T. Truth is not determined by a majority vote. Gastroenterology. 2003;124:11535. [DOI] [PubMed]
    Sugano K. Effect of Helicobacter pylori eradication on the incidence of gastric cancer: a systematic review and meta-analysis. Gastric Cancer. 2019;22:43545. [DOI] [PubMed]
    Choi YK, Ahn JY, Won SH, Jung K, Na HK, Jung KW, et al. Eradication rate of Helicobacter pylori reinfection in Korea: a retrospective study. J Gastroenterol Hepatol. 2019;34:1696702. [DOI] [PubMed]
    Xie Y, Song C, Cheng H, Xu C, Zhang Z, Wang J, et al. Long-term follow-up of Helicobacter pylori reinfection and its risk factors after initial eradication: a large-scale multicentre, prospective open cohort, observational study. Emerg Microbes Infect. 2020;9:54857. [DOI] [PubMed] [PMC]
    Zhang L, Chen X, Ren B, Zhou X, Cheng L. Helicobacter pylori in the oral cavity: current evidence and potential survival strategies. Int J Mol Sci. 2022;23:13646. [DOI] [PubMed] [PMC]
    Zhao JB, Yuan L, Yu XC, Shao QQ, Ma J, Yu M, et al. Whole family—based Helicobacter pylori eradication is a superior strategy to single-infected patient treatment approach: a systematic review and meta-analysis. Helicobacter. 2021;26:e12793. [DOI] [PubMed]
    Shatila M, Thomas AS. Current and future perspectives in the diagnosis and management of Helicobacter pylori infection. J Clin Med. 2022;11:5086. [DOI] [PubMed] [PMC]
    Kuo YT, Liou JM, El-Omar EM, Wu JY, Leow AHR, Goh KL, et al. Primary antibiotic resistance in Helicobacter pylori in the Asia-Pacific region: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol. 2017;2:70715. [DOI] [PubMed]
    Ford AC, Gurusamy KS, Delaney B, Forman D, Moayyedi P. Eradication therapy for peptic ulcer disease in Helicobacter pylori-positive people. Cochrane Database Syst Rev. 2016;4:CD003840. [DOI] [PubMed] [PMC]
    Beg S, Ragunath K, Wyman A, Banks M, Trudgill N, Pritchard DM, et al. Quality standards in upper gastrointestinal endoscopy: a position statement of the British Society of Gastroenterology (BSG) and Association of Upper Gastrointestinal Surgeons of Great Britain and Ireland (AUGIS). Gut. 2017;66:188699. [DOI] [PubMed] [PMC]
    Malfertheiner P, Chan FK, McColl KE. Peptic ulcer disease. Lancet. 2009;374:144961. [DOI] [PubMed]
    Musumba C, Jorgensen A, Sutton L, Van Eker D, Moorcroft J, Hopkins M, et al. The relative contribution of NSAIDs and Helicobacter pylori to the aetiology of endoscopically-diagnosed peptic ulcer disease: observations from a tertiary referral hospital in the UK between 2005 and 2010. Aliment Pharmacol Ther. 2012;36:4856. [DOI] [PubMed]
    Bang CS, Lee JJ, Baik GH. Prediction of chronic atrophic gastritis and gastric neoplasms by serum pepsinogen assay: a systematic review and meta-analysis of diagnostic test accuracy. J Clin Med. 2019;8:657. [DOI] [PubMed] [PMC]
    Sung JJY. Population-based screening and mass eradication of Helicobacter pylori infection to prevent gastric cancer: There are more questions than answers. J Gastroenterol Hepatol. 2020;35:5212. [DOI] [PubMed]
    Fitzpatrick C, Asiedu K, Solomon AW, Mitja O, Marks M, Van der Stuyft P, et al. Prioritizing surveillance activities for certification of yaws eradication based on a review and model of historical case reporting. PLoS Negl Trop Dis. 2018;12:e0006953. [DOI] [PubMed] [PMC]
    Sutton P, Boag JM. Status of vaccine research and development for Helicobacter pylori. Vaccine. 2019;37:72959. [DOI] [PubMed] [PMC]
    Ding SZ, Du YQ, Lu H, Wang WH, Cheng H, Chen SY, et al.; National Clinical Research Center for Digestive Diseases (Shanghai); Gastrointestinal Early Cancer Prevention & Treatment Alliance of China (GECA); Helicobacter pylori Study Group of Chinese Society of Gastroenterology; Chinese Alliance for Helicobacter pylori Study. Chinese consensus report on family-based Helicobacter pylori infection control and management (2021 edition). Gut. 2022;71:23853. [DOI] [PubMed] [PMC]
    Salar A. Gastric MALT lymphoma and Helicobacter pylori. Med Clin (Barc). 2019;152:6571. [DOI] [PubMed]
    Zhao Y, Li Y, Hu J, Wang X, Ren M, Lu G, et al. The Effect of Helicobacter pylori eradication in patients with gastroesophageal reflux disease: a meta-analysis of randomized controlled studies. Dig Dis. 2020;38:2618. [DOI] [PubMed]
    Shah SC, Iyer PG, Moss SF. AGA clinical practice update on the management of refractory Helicobacter pylori infection: expert review. Gastroenterology. 2021;160:183141. [DOI] [PubMed] [PMC]
    Nei T, Hagiwara J, Takiguchi T, Yokobori S, Shiei K, Yokota H, et al. Fatal fulminant Clostridioides difficile colitis caused by Helicobacter pylori eradication therapy; a case report. J Infect Chemother. 2020;26:3058. [DOI] [PubMed]
    Tanaka K, Fujiya M, Sakatani A, Fujibayashi S, Nomura Y, Ueno N, et al. Second-line therapy for Helicobacter pylori eradication causing antibiotic-associated hemorrhagic colitis. Ann Clin Microbiol Antimicrob. 2017;16:54. [DOI] [PubMed] [PMC]
    Tonneau M, Nolin-Lapalme A, Kazandjian S, Auclin E, Panasci J, Benlaifaoui M, et al. Helicobacter pylori serology is associated with worse overall survival in patients with melanoma treated with immune checkpoint inhibitors. Oncoimmunology. 2022;11:2096535. [DOI] [PubMed] [PMC]
    Oster P, Vaillant L, Riva E, McMillan B, Begka C, Truntzer C, et al. Helicobacter pylori infection has a detrimental impact on the efficacy of cancer immunotherapies. Gut. 2022;71:45766. [DOI] [PubMed] [PMC]
    Che H, Xiong Q, Ma J, Chen S, Wu H, Xu H, et al. Association of Helicobacter pylori infection with survival outcomes in advanced gastric cancer patients treated with immune checkpoint inhibitors. BMC Cancer. 2022;22:904. [DOI] [PubMed] [PMC]